Mirati Therapeutics Inc $ 104.33 1.15 (1.11%)
Volume:
271,872
Avg Vol (1m):
663,625
Market Cap $:
4.11 Bil
Enterprise Value $:
3.66 Bil
P/E (TTM):
0.00
P/B:
9.41
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
|
Price: $104.33 | ||
Manual of Stocks™ Web
Financial Strength | 10/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | No Debt | ||
| Equity-to-Asset | 0.92 | ||
| Interest Coverage | No Debt | ||
| Piotroski F-Score | 4 | ||
| Beneish M-Score | -2.97 | ||
Profitability | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -2825.94 | ||
| Net Margin % | -2691.53 | ||
| ROE % | -52.16 | ||
| ROA % | -47.99 | ||
| ROC (Joel Greenblatt) % | -38339.83 | ||
| 3-Year EBITDA Growth Rate | 4.6 | ||
| 3-Year EPS without NRI Growth Rate | 5.9 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 9.41 | ||
| PS Ratio | 570.11 | ||
| EV-to-EBIT | -20.68 | ||
| EV-to-EBITDA | -20.7 | ||
| EV-to-Revenue | 583.95 | ||
| Current Ratio | 13.15 | ||
| Quick Ratio | 13.15 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.4 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 9.41 | ||
| Price-to-Median-PS-Value | 4.22 | ||
| Earnings Yield (Greenblatt) % | -4.83 |